SEC Form 4 · accession 0001562180-18-004259
REGENXBIO Inc. · RGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick J. Christmas
Officer — SVP, General Counsel
Period of report
Oct 18, 2018
Accepted (ET)
Oct 22, 2018 · 4:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590877
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 18, 2018 | M | 5,000 | $12.10 | A | 22,669 | D | |
| Common StockF2 | Oct 18, 2018 | S | 1,500 | $61.22 | D | 21,169 | D | |
| Common StockF3 | Oct 18, 2018 | S | 3,410 | $62.00 | D | 17,759 | D | |
| Common Stock | Oct 18, 2018 | S | 90 | $62.67 | D | 17,669 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F4 | $12.10 | Oct 18, 2018 | M | 5,000 | D | — | Aug 17, 2026 | Common Stock | 5,000 | 58,472 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- F2This transaction was executed in multiple trades at prices ranging from $60.63 to $61.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $61.65 to $62.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.